@ImmunityBio Avatar @ImmunityBio ImmunityBio, Inc.

ImmunityBio, Inc. posts on X about in the, future, science, health the most. They currently have [------] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.

Engagements: [-----] #

Engagements Line Chart

Mentions: [--] #

Mentions Line Chart

Followers: [------] #

Followers Line Chart

CreatorRank: [---------] #

CreatorRank Line Chart

Social Influence

Social category influence countries 6.73% finance 3.85% travel destinations 0.96%

Social topic influence in the 12.5%, future 10.58%, science #4598, health 6.73%, we are 5.77%, $ibrx #13, united states 4.81%, the first 4.81%, vision 4.81%, matter 2.88%

Top accounts mentioned or mentioned by @petitnong_ @drpatrick @saiseiinvesting @jayosays @phoenxlights @garyr9912 @meeradnan89945 @truedat999 @oshin76 @xrphomie @maschotta_adam @foreveruseless_ @epboston @bladdercancerus @oncodaily @bullishbruk @daviddin @tteuscher @aponiaanalytics @galactiator

Top assets mentioned ImmunityBio, Inc. Common Stock (IBRX)

Top Social Posts

Top posts by engagements in the last [--] hours

"We've announced our new study called COVID-4.019-Long which further expands our clinical research efforts to assess ANKTIVAs potential beyond cancer or cancer-related diseases. Learn more about the study and its potential impact: https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-phase-2-study-anktivar-patients-long-covidfield_nir_news_date_valuemin= https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-phase-2-study-anktivar-patients-long-covidfield_nir_news_date_valuemin="
X Link 2025-08-19T12:45Z 16.5K followers, 19.2K engagements

"At ImmunityBio our pipeline continues to expand with chemotherapy-free approaches designed to harness the power of one's own immune system. We have launched ResQ215B a Phase [--] clinical study evaluating a novel chemotherapy-free and lymphodepletion-free combination immunotherapy in patients with indolent B-cell non-Hodgkin lymphoma (iNHL) including Waldenstrms Macroglobulinemia. Learn more: https://immunitybio.com/immunitybio-launches-phase-2-chemotherapy-free-car-nk-cell-therapy-trial-with-anktiva%ef%83%92-resq215b-in-indolent-lymphomas/"
X Link 2026-02-02T15:15Z 16.5K followers, 61.4K engagements

"Progress isn't measured only in milestones but in its impact on people. At ImmunityBio our work is centered on translating scientific innovation into outcomes that matter. Explore what's next in our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2026-02-09T16:31Z 16.5K followers, [----] engagements

"Glioblastoma presents significant scientific and clinical challenges for patients and healthcare providers. The disease's limited treatment options emphasize the need for continued research and deeper scientific understanding. Our efforts in the glioblastoma space are focused on advancing studies designed to better comprehend the cancer and explore innovative therapeutic approaches. Learn more about ImmunityBio's glioblastoma clinical trial: https://immunitybio.com/glioblastoma/ https://immunitybio.com/glioblastoma/"
X Link 2026-02-12T15:20Z 16.5K followers, 21.9K engagements

"ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patients immune system not weakening it. View our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2025-10-06T15:45Z 16.4K followers, [----] engagements

"This National Urology Nurses Week ImmunityBio recognizes the dedication and expertise of urology nurses who provide compassionate care to patients every day. Your commitment helps improve outcomes and quality of life for individuals navigating urologic conditions including bladder cancer. Thank you for all that you do. https://twitter.com/i/web/status/1985360359205794185 https://twitter.com/i/web/status/1985360359205794185"
X Link 2025-11-03T14:56Z 16.5K followers, [----] engagements

"Bladder Health Month provides us with an opportunity to reflect on the progress made through science and the compassion that drives it forward. Behind every clinical advancement are patients nurses physicians and caretakers determined to improve the future of bladder cancer care. We share that mission - to transform how bladder cancer is treated and to restore the body's ability to fight disease. Together with organizations like @BladderCancerUS and @UrologyCareFdn we work toward a future defined by better outcomes and renewed hope. https://twitter.com/i/web/status/1986084840928924003"
X Link 2025-11-05T14:55Z 16.5K followers, [----] engagements

"Every November Lung Cancer Awareness Month shines a light on the importance of education early detection and innovation. ImmunityBio is proud to support this awareness by pursuing scientific advancements designed to improve outcomes for patients facing lung cancer. Learn more: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/"
X Link 2025-11-07T14:58Z 16.5K followers, [----] engagements

"The [----] National Health Interview Survey shows a powerful truth: if lung cancer screenings were to reach 100% [-----] lives could be saved in a mere five years. As we recognize Lung Cancer Awareness Month insights like this reinforce why ImmunityBio is investing in new approaches that aim to expand treatment options and address the challenges in lung cancer care. https://twitter.com/i/web/status/1991937478379626553 https://twitter.com/i/web/status/1991937478379626553"
X Link 2025-11-21T18:31Z 16.4K followers, [----] engagements

"While the exact cause of glioblastoma remains unknown several risk factors have been linked to increased risk - including age gender prior exposure to radiation and rare genetic conditions. For many patients however glioblastoma develops without a clear identifiable cause. At ImmunityBio we're conducting clinical research to better understand glioblastoma and evaluate investigational therapies that may offer new options for patients facing this difficult diagnosis. To learn more about our research visit https://immunitybio.com/glioblastoma/ https://immunitybio.com/glioblastoma/"
X Link 2025-12-01T17:57Z 16.4K followers, [----] engagements

"Our Founder and Executive Chairman Dr. Patrick Soon-Shiong had the honor of carrying the Olympic torch in Athens at the historic stadium - representing Los Angeles and the United States as the flame was passed to Italy for the [----] Games"
X Link 2025-12-05T15:42Z 16.4K followers, [----] engagements

"ANKTIVA plus BCG has received a positive recommendation for marketing authorization in the EU for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) with or without papillary tumors. The recommendation reflects the EMAs determination that earlier patient access is warranted and represents an important step forward for individuals with BCG-unresponsive disease an area with otherwise limited treatment options. Learn more:"
X Link 2025-12-12T12:15Z 16.4K followers, 59.4K engagements

"Lymphopenia can be a significant concern for patients with cancer as both chemotherapy and radiation can markedly lower lymphocyte levels. Reduced immune cell counts may affect how patients tolerate treatment and respond to infections. Learn more about how we're working to address lymphopenia for better patient outcomes: https://immunitybio.com/lymphopenia/ https://immunitybio.com/lymphopenia/"
X Link 2025-12-15T14:57Z 16.4K followers, [----] engagements

"The European Medicines Agency has granted conditional marketing authorization for ANKTIVA + BCG for patients with BCG-unresponsive NMIBC CIS in the European Union. This gives eligible patients in the EU access to our innovative treatment. Once the European Commission (EC) gives its final approval it will broadly expand the reach of ANKTIVA from two to [--] nations including the U.K. and U.S. Learn more:"
X Link 2025-12-19T16:51Z 16.4K followers, [----] engagements

"Firefighters face a higher risk of bladder cancer and other cancers due to repeated exposure to carcinogens in the line of duty. While they dedicate their lives to protecting others their own health is often put at risk in the process. During Firefighter Cancer Awareness Month ImmunityBio remains focused on supporting efforts that increase awareness of cancer risk promote informed conversations between patients and healthcare providers and advance research aimed at improving outcomes for those affected by non-muscle invasive bladder cancer. https://twitter.com/i/web/status/2007102939631136897"
X Link 2026-01-02T14:53Z 16.4K followers, [----] engagements

"In [----] the International Agency for Research on Cancer (IARC) classified firefighting as a Class [--] carcinogenic occupation the highest level of evidence linking an exposure to cancer in humans. This designation reflects consistent documentation that firefighters encounter carcinogens through multiple pathways including: inhalation of toxic smoke dermal absorption of chemicals and contaminated turnout gear and equipment. These exposure have been associated with an increased risk of several cancers including bladder cancer. Understanding these exposure pathways is essential to advancing"
X Link 2026-01-06T14:43Z 16.4K followers, [----] engagements

"You can help shape the future of cancer treatment by joining the ImmunityBio team. We're hiring passionate individuals committed to advancing research and developing innovative therapies that improve patient outcomes. Start your journey with us: https://immunitybio.com/careers/ https://immunitybio.com/careers/"
X Link 2026-01-09T16:16Z 16.4K followers, [----] engagements

"We've announced the Inaugural U.S.-Saudi Biotech Alliance Summit which will bring together national leaders from the United States and the Kingdom of Saudi Arabia across government healthcare delivery biotechnology advanced manufacturing artificial intelligence and finance. The Summit is designed to foster implementation and collaboration to accelerate the development manufacturing and global deployment of next-generation immunotherapies and healthcare technologies. Learn more:"
X Link 2026-01-12T18:36Z 16.4K followers, [----] engagements

"New data demonstrates that ANKTIVA enhances immune restoration when combined with checkpoint inhibitors in NSCLC with statistically significant increases in absolute lymphocyte counts and corresponding survival benefits that reinforce its role as a promising lymphocyte-stimulating agent. Read more: https://immunitybio.com/immunitybio-announces-positive-results-demonstrating-anktiva-as-a-lymphocyte-stimulating-agent-in-combination-with-checkpoint-inhibitors-in-non-small-cell-lung-cancer/"
X Link 2026-01-13T15:03Z 16.4K followers, 59.7K engagements

"Today the Saudi Food and Drug Authority (SFDA) granted accelerated approval of ANKTIVA for use in combination with immune checkpoint inhibitors for adult patients with metastatic NSCLC whose disease has progressed following standard-of-care therapy. This marks the first approval anywhere in the world for ANKTIVA in this indication. Learn more: https://immunitybio.com/saudi-fda-grants-accelerated-approval-to-immunitybios-anktiva-in-combination-with-checkpoint-inhibitors-for-metastatic-non-small-cell-lung-cancer/"
X Link 2026-01-14T15:30Z 16.4K followers, 14.3K engagements

"At ImmunityBio we reported approximately $113 million in preliminary net product revenue for [----] representing a 700% year-over-year increase. This continued momentum reflects steady execution and growing adoption of ANKTIVA - and most importantly progress toward our mission to advance therapies designed to restore the bodys natural ability to fight cancer. Read more: https://immunitybio.com/immunitybio-reports-continued-execution-and-sales-momentum-with-113-million-of-preliminary-net-product-revenue-a-700-increase-year-over-year/"
X Link 2026-01-15T15:28Z 16.4K followers, 14.5K engagements

"Dr. Patrick Soon-Shiong ImmunityBio's Founder Executive Chairman and Global Chief Scientific and Medical Officer also met with His Excellency Dr Bandar Alknawy to discuss the role of King Abdullah International Medical Research Center (KAIMRC) in advancing Saudi Arabias National Biotechnology Strategy. Their conversation highlighted how KAIMRC is contributing to scientific innovation health resilience and long-term economic growth key pillars of Vision [----]. Together these efforts reflect a shared commitment to strengthening international research capabilities and positioning biotechnology as"
X Link 2026-01-15T20:13Z 16.4K followers, 33.8K engagements

"Were continuing to advance our first-line BCG-nave non-muscle invasive bladder cancer program with enrollment exceeding expectations in our randomized registrational trial evaluating ANKTIVA plus BCG. These early milestones underscore our continued focus on moving this program forward and addressing unmet needs in bladder cancer. Read more: https://immunitybio.com/immunitybio-advances-first-line-bcg-naive-nmibc-program-with-enrollment-exceeding-expectations-and-positive-interim-analysis-for-anktiva-plus-bcg/"
X Link 2026-01-16T15:33Z 16.4K followers, 10.1K engagements

"Cancer is a leading cause of death among firefighters accounting for approximately 66% of firefighter line-of-duty deaths according to the Firefighter Cancer Support Network. These exposures have been linked to elevated cancer risk across multiple sites including bladder cancer. Our work is informed by the realities of occupational cancer risk and underscores the importance of continued research that focuses on improving outcomes for affected patients. Learn more about our efforts in the bladder cancer space: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2026-01-19T17:38Z 16.4K followers, [----] engagements

"ImmunityBio reported that median overall survival has not yet been reached in patients with recurrent or progressive glioblastoma treated with a chemo-free ANKTIVA + CAR-NK-based regimen. As recent @AmericanCancer data shows that brain cancer is now the third leading cause of cancer-related death among adults ages [----] these findings underscore the urgency of continued innovation in this disease. Read more: https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-reports-median-overall-survival-not-yet-reached-andfield_nir_news_date_value%5Bmin%5D="
X Link 2026-01-23T12:19Z 16.4K followers, 105.9K engagements

"Firefighters face danger every day both visible and unseen. Research has shown that firefighters are at an increased risk for certain cancers including bladder cancer making awareness and timely diagnosis critical. Our advancements in bladder cancer are guided by a mission to improve outcomes and expand treatment possibilities. Learn more about what ImmunityBio is doing in the bladder cancer space: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2026-01-26T15:32Z 16.4K followers, [----] engagements

"World Cancer Day serves as a reminder of the determination resilience and strength behind every cancer patient's journey - and the importance of continued progress in care. Our work is driven by the responsibility to move cancer research forward to deliver meaningful outcomes and help shape a more hopeful future for patients. https://twitter.com/i/web/status/2019082540792127800 https://twitter.com/i/web/status/2019082540792127800"
X Link 2026-02-04T16:16Z 16.4K followers, [----] engagements

"Progress in non-muscle invasive bladder cancer (NMIBC) depends on continued innovation in how the disease is treated and managed over time. As patients and healthcare providers navigate complex care decisions ImmunityBio is advancing new therapeutic approaches designed to support improved outcomes. Learn more: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2026-01-20T18:36Z 16.5K followers, 11K engagements

"Weve announced new paradigm-changing findings from the Phase [--] QUILT-3.055 study demonstrating ANKTIVA (nogapendekin alfa inbakicept-pmln) reverses lymphopenia (low natural killer and T cells) in patients with checkpoint inhibitor-resistant advanced non-small cell lung cancer (NSCLC) with this reversal resulting in significant prolonged median overall survival (mOS). Read more: https://immunitybio.com/immunitybios-anktiva-reverses-lymphopenia-and-extends-overall-survival-in-patients-with-advanced-non-small-cell-lung-cancer-resistant-to-checkpoint-therapy/"
X Link 2025-09-08T13:25Z 16.5K followers, 13.4K engagements

"Her Royal Highness Princess Dr. Haya Al Saud joined ImmunityBios Founder Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong for a discussion on the future of human health and resilience. As a leader of the Hevolution Foundation Princess Haya Al Saud shared a powerful vision for longevity science: emphasizing the importance of strengthening biology and expanding how progress is measured. My dream would be to make healthspan a measure of GDP. https://twitter.com/i/web/status/2011512082588631521 https://twitter.com/i/web/status/2011512082588631521"
X Link 2026-01-14T18:53Z 16.5K followers, 77.9K engagements

"At this weeks MAHA Media Hub Dr. Patrick Soon-Shiong Founder Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio shared insights on the evolving understanding of cancer and why advancing beyond traditional treatment paradigms is essential. His perspective underscored the importance of rethinking how we approach cancer with a focus on science-driven innovation and the bodys own immune system as a critical part of the solution. Watch now: https://immunitybio.com/maha-action-media-hub/ https://immunitybio.com/maha-action-media-hub/"
X Link 2026-01-30T16:52Z 16.5K followers, 18.5K engagements

"ImmunityBio Founder Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong recently joined the @OncBrothers podcast to explore the science and patient impact behind what it takes to be a true game-changer in oncology. This wasnt just a discussion about a drug but a conversation about rebuilding the immune system and rethinking what the future of cancer care must look like. Listen in and hear how ImmunityBio is pushing immunotherapy forward starting with the immune system itself: https://www.youtube.com/watchv=aRDyqswYUOY&t=4s"
X Link 2026-02-09T20:13Z 16.5K followers, 95.8K engagements

"As a company that believes medicine should not only treat but transform lives we pursue outcomes that matter. Our team is deeply connected to this mission many of us driven by personal experiences that fuel our commitment. In every breakthrough there is a shared drive to make a difference - because for us this work is personal. https://twitter.com/i/web/status/2022395824358257024 https://twitter.com/i/web/status/2022395824358257024"
X Link 2026-02-13T19:41Z 16.5K followers, [----] engagements

"Advanced ovarian cancer presents significant challenges especially for this with platinum-resistant recurrence. ImmunityBio is working on potential solutions through our clinical trial for recurrent platinum-resistant high-grade ovarian cancer. Our goal is to provide new hope where options are limited. Visit our website to learn more: https://immunitybio.com/ovarian-cancer/ https://immunitybio.com/ovarian-cancer/"
X Link 2025-06-10T16:33Z 16.5K followers, [----] engagements

"At ImmunityBio our commitment to innovation drives us to explore new frontiers in medicine. From addressing genetic disorders like Lynch syndrome to tackling complex cancers such as bladder cancer we are dedicated to making a meaningful impact. Join us in our journey to transform the future of healthcare by viewing our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2025-06-13T14:30Z 16.5K followers, [----] engagements

""Smart therapies for difficult diseases" isn't just a phrase - it is the foundation of everything we do. At ImmunityBio we're working to transform how cancer is treated by designing therapies that not only target disease but restore the body's natural ability to fight it. View our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2025-06-16T14:43Z 16.5K followers, [----] engagements

"Annually over [------] people in the United States are diagnosed with lung cancer with the majority facing non-small cell lung cancer (NSCLC). We're working to enhance the activity of NK and T cells empowering the immune system to better combat NSCLC. Learn more about our approach: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/"
X Link 2025-06-19T14:11Z 16.5K followers, [----] engagements

"Lymphopenia is a serious condition affecting many patients with cancer - especially those undergoing chemotherapy or radiation. It can leave the immune system compromised and limit the body's ability to fight illness. We're working to address this challenge through our science and ongoing clinical research with a goal of improving outcomes by enhancing immune recovery. https://twitter.com/i/web/status/1937512789037449583 https://twitter.com/i/web/status/1937512789037449583"
X Link 2025-06-24T14:07Z 16.5K followers, [----] engagements

"Join us in transforming the future of cancer treatment. ImmunityBio is advancing innovative therapies that bring new hope to patients facing some of the most challenging cancers. We're looking for passionate mission-driven individuals to grow with us. Be a part of something bigger. Explore open positions and apply today: https://immunitybio.com/careers/ https://immunitybio.com/careers/"
X Link 2025-06-26T15:05Z 16.5K followers, [----] engagements

"Bladder cancer recurrence is a reality for nearly half of patients with non-muscle invasive disease. ImmunityBio is advancing immunotherapy-based research to help the body's own defenses recognize and fight cancer. Learn more: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2025-07-02T13:44Z 16.5K followers, [----] engagements

"On this Independence Day we recognize the sacrifices made for our freedom and the strength of the communities that continue to move our nation forward. The team at ImmunityBio wishes you a safe and happy holiday"
X Link 2025-07-04T17:09Z 16.5K followers, [----] engagements

"Today we announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted the first marketing approval outside the United States for this novel lymphocyte-stimulating agent ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Gurin (BCG) for the treatment of certain bladder cancer patients. Learn more: https://immunitybio.com/uk-mhra-approves-immunitybios-anktiva-plus-bcg-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-carcinoma-in-situ/"
X Link 2025-07-08T02:01Z 16.5K followers, [----] engagements

"Our scientists are working to develop remarkable new therapies that harness the body's inherent power by amplifying both the innate and adaptive branches of the immune system facilitating the attack and elimination of cancerous or infected cells today while building immunological memory for tomorrow. Learn more: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2025-07-10T14:35Z 16.5K followers, [----] engagements

"According to the American Cancer Society lung cancer accounts for nearly [--] in [--] cancer deaths in the United States. ImmunityBio is focused on developing therapies that address this ongoing health challenge. Read more: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/"
X Link 2025-07-15T14:28Z 16.5K followers, [----] engagements

"Our scientists translate rigorous immunology research into innovative cell- and immune-based therapies working every day to expand treatment options and improve outcomes for patients"
X Link 2025-07-21T16:30Z 16.5K followers, [----] engagements

"Weve reported a 60% revenue increase in Q2 [----] with year-to-date sales reaching $43M and a 246% growth in ANKTIVA sales since J-code issuance. Regulatory milestones continue to help us advance our mission of improving outcomes for patients. Read more: https://immunitybio.com/immunitybio-reports-60-increase-in-revenue-in-q2-2025-with-year-to-date-sales-of-43-million-and-246-unit-growth-since-j-code-with-regulatory-updates/ https://immunitybio.com/immunitybio-reports-60-increase-in-revenue-in-q2-2025-with-year-to-date-sales-of-43-million-and-246-unit-growth-since-j-code-with-regulatory-updates/"
X Link 2025-07-25T16:16Z 16.5K followers, [----] engagements

"Lymphopenia remains a critical challenge for patients undergoing cancer treatment often compromising immune function and increasing the risk of complications. At ImmunityBio we are advancing clinical research aimed at promoting immune system recover and improving long-term outcomes for patients. Learn more: https://immunitybio.com/lymphopenia/ https://immunitybio.com/lymphopenia/"
X Link 2025-07-29T19:39Z 16.5K followers, [----] engagements

"We believe our science has the potential to change the current paradigm of care for patients. Through a combination of highly experienced and talented people deep scientific knowledge and advanced research and manufacturing facilities ImmunityBio aims to improve outcomes for those living with difficult-to-treat diseases. Learn more about our founder's vision: https://immunitybio.com/founders-vision/ https://immunitybio.com/founders-vision/"
X Link 2025-08-04T18:00Z 16.5K followers, [----] engagements

"Bladder cancer incidence is rising but so are the options for patients facing this diagnosis. At ImmunityBio we are working to improve outcomes and reduce the burden of treatment for patients with non-muscle invasive bladder cancer. As the need grows so does our commitment to developing solutions designed to harness the body's own immune system. https://twitter.com/i/web/status/1953111107784327668 https://twitter.com/i/web/status/1953111107784327668"
X Link 2025-08-06T15:09Z 16.5K followers, [----] engagements

"Veterans are at an increased risk for bladder cancer due to exposure to carcinogens during service. Houston's Michael E. DeBakey VA Medical Center is now among the first VA hospitals to offer ANKTIVA for eligible veterans with BCG-unresponsive NMIBC. Read more: https://immunitybio.com/immunitybio-announces-houstons-michael-e-debakey-va-medical-center-is-among-the-first-va-hospitals-to-administer-anktiva-to-bladder-cancer-patients/"
X Link 2025-08-11T14:16Z 16.5K followers, [----] engagements

"Our robust pipeline of clinical trials is all about turning insights into better outcomes for people facing a wide range of cancers. The ImmunityBio team remains committed to transforming research into tangible impact in the lives of patients. Explore our latest trials: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2025-08-12T15:56Z 16.5K followers, [----] engagements

"We announced early results from our QUILT-106 Phase I trial showing complete responses in the first two late-stage Non-Hodgkin Waldenstrm lymphoma patients treated with our CD19 CAR-NK cell therapy. Learn more: https://immunitybio.com/immunitybio-reports-complete-responses-in-non-hodgkin-waldenstrom-lymphoma-patients-with-chemotherapy-free-first-in-class-cd19-car-nk-immunotherapy/ https://immunitybio.com/immunitybio-reports-complete-responses-in-non-hodgkin-waldenstrom-lymphoma-patients-with-chemotherapy-free-first-in-class-cd19-car-nk-immunotherapy/"
X Link 2025-08-13T13:14Z 16.5K followers, 96.5K engagements

"Weve announced that our initial data shows 100% disease control in [--] out of [--] patients with recurrent glioblastoma after being treated with our ANKTIVA NK cell therapy plus the Optune Gio device. Read more: https://immunitybio.com/initial-data-shows100-disease-control-in-5-out-of-5-patients-with-recurrent-glioblastoma-with-two-patients-in-near-complete-response-treated-with-immunitybios-anktiva-nk-cell-therapy-p/"
X Link 2025-08-26T12:46Z 16.5K followers, 37.6K engagements

"We're focused on innovating beyond standard treatments so that we can give the body the tools it needs to lead its own fight against cancer. Learn more about our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2025-09-02T14:25Z 16.5K followers, [----] engagements

"September marks Ovarian Cancer Awareness Month; a time to highlight the importance of early detection and ongoing research in the fight against this disease. Our team is always striving to push the boundaries of what is possible in ovarian cancer treatment. This month and every month we're dedicated to supporting patients and driving research forward. Learn more about our trial: https://immunitybio.com/ovarian-cancer/ https://immunitybio.com/ovarian-cancer/"
X Link 2025-09-03T20:20Z 16.5K followers, [----] engagements

"With high rates of recurrence and the risk of advancing disease non-muscle invasive bladder cancer (NMIBC) remains a significant burden for both patients and healthcare providers. ImmunityBio is working to meet this challenge through the development of innovative treatment approached aimed at addressing the disease more effectively. Learn more: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2025-09-16T15:54Z 16.4K followers, [----] engagements

"Lung cancer remains one of the leading causes of cancer-related deaths worldwide. At ImmunityBio we are advancing clinical research to explore new treatment options that harness the immune system. Our goal is to help expand possibilities for patients facing this disease. Learn more about our research: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/"
X Link 2025-09-24T18:37Z 16.4K followers, [----] engagements

"The team at ImmunityBio extends our congratulations to Dr. Mary E. Brunkow Dr. Fred Ramsdell and Dr. Shimon Sakaguchi recipients of the [----] Nobel Prize in Physiology or Medicine. This groundbreaking research on regulatory T cells has advanced the scientific understanding of immune tolerance providing the foundation for developing novel therapies targeting cancer and infectious diseases. We recognize and applaud their contributions to immunology which continue to inspire innovation. Read more: https://www.nobelprize.org/prizes/medicine/2025/press-release/"
X Link 2025-10-08T14:37Z 16.5K followers, [----] engagements

"Addressing the complexities of cancer and infectious diseases fuels our pursuit of new therapies that provide better outcomes for patients. If you're looking for a career with purpose become a part of our innovative team: https://immunitybio.com/careers/ https://immunitybio.com/careers/"
X Link 2025-10-14T14:40Z 16.5K followers, [----] engagements

"This weekend's BCAN Patient Summit in Columbus brought together patients caregivers and healthcare professionals united in their commitment to improving outcomes and quality of life for those affected by bladder cancer. We're proud to stand alongside @BladderCancerUS and the broader advocacy community in this mission. https://twitter.com/i/web/status/1980289869403533722 https://twitter.com/i/web/status/1980289869403533722"
X Link 2025-10-20T15:07Z 16.5K followers, [----] engagements

"At ImmunityBio we're dedicated to pushing the boundaries of medical research. By participating in our clinical trials individuals help us innovate and shape the future of cancer and infectious disease treatment. Learn more: https://immunitybio.com/find-a-trial/ https://immunitybio.com/find-a-trial/"
X Link 2025-10-27T15:22Z 16.4K followers, [----] engagements

"We reported another quarter of strong results driven by increased demand for ANKTIVA and continued progress across our immunotherapy pipeline. In Q3 [----] we achieved significant year-to-date unit growth of 467% and $75 million in total product sales reflecting growing adoption in BCG-unresponsive non-muscle invasive bladder cancer. As we close out the year we remain committed to expanding access to our therapies advancing ongoing trials across multiple indications and executing our long-term vision to transform how cancer is treated. Read the full release including important cautionary"
X Link 2025-11-06T18:23Z 16.5K followers, [----] engagements

"Hope moves science forward. This month we honor the strength of the bladder cancer community and remain committed to transforming the treatment landscape through therapies that empower the immune system to fight cancer more effectively"
X Link 2025-11-10T15:34Z 16.5K followers, [----] engagements

"This Veterans Day we reflect on the sacrifices made by those who served our country and the importance of improving health outcomes for veterans living with cancer and other serious diseases. Their resilience drives our ongoing pursuit of better care for all patients. Thank you. https://twitter.com/i/web/status/1988256773657292939 https://twitter.com/i/web/status/1988256773657292939"
X Link 2025-11-11T14:45Z 16.5K followers, [----] engagements

"A recent Harris survey found that a vast majority of patients with non-muscle invasive bladder cancer (NMIBC) see intravesical chemotherapy as a last resort whereas 72% of immunotherapy recipients are satisfied with the duration of positive treatment effects. With patients at the forefront ImmunityBio continues to focus on innovative approaches designed to preserve bladder function and improve quality of life for those facing difficult treatment decisions. Read more here: https://immunitybio.com/new-survey-reveals-non-muscle-invasive-bladder-cancer-patients-seek-more-care-conversations/"
X Link 2025-11-13T14:14Z 16.4K followers, [----] engagements

"During our National Sales Meeting we came together to align on our vision for the year ahead; one rooted in innovation collaboration and meaningful impact. From inspiring presentations to strategy sessions every moment reinforced our dedication to driving progress for patients. We leave this meeting energized and focused on the work matters most - making a lasting difference in cancer care. https://twitter.com/i/web/status/1989382511408156911 https://twitter.com/i/web/status/1989382511408156911"
X Link 2025-11-14T17:18Z 16.4K followers, [----] engagements

"Lung Cancer Awareness Month is a time to recognize the progress made and the work still ahead. Non-small cell lung cancer (NSCLC) accounts for over 85% of all lung cancer cases in the U.S. with more than [------] diagnoses each year. Our work focuses on developing immunotherapy treatments that strengthen the body's natural immune response to target and destroy cancer cells. Through clinical research and collaboration we aim to deliver treatments that extend survival and improve quality of life for those affected. Learn more about our NSCLC clinical trial:"
X Link 2025-11-17T16:59Z 16.4K followers, [----] engagements

"We're honored to collaborate with the Saudi leadership team as we work to advance research and identify opportunities to reach more patients in need"
X Link 2025-11-20T16:49Z 16.4K followers, 12.9K engagements

"Our Founder and Executive Chairman Dr. Patrick Soon-Shiong recently sat down with @ChrisCuomo to share insights on the evolving landscape of cancer research and scientific innovation. Watch Killing Cancer Tuesday November [--] at 10p/9C on NewsNation"
X Link 2025-11-20T20:10Z 16.4K followers, [----] engagements

"As we reflect on this past year were reminded of the many things we hold with gratitude - our dedicated team the physicians and caregivers who make exceptional care possible and the patients whose resilience inspires every step forward. Together were continuing to advance science in the pursuit of better outcomes for those facing cancer. https://twitter.com/i/web/status/1994178833239691757 https://twitter.com/i/web/status/1994178833239691757"
X Link 2025-11-27T22:57Z 16.4K followers, [----] engagements

"We look forward to participating in the Society of Urologic Oncology's 26th Annual Meeting. Opportunities for collaboration at these meetings are essential in advancing new breakthroughs in bladder cancer care and we're committed to contributing to ongoing innovation in the space. @UroOnc https://twitter.com/i/web/status/1995955710400791008 https://twitter.com/i/web/status/1995955710400791008"
X Link 2025-12-02T20:38Z 16.4K followers, [----] engagements

"Patient voices matter. According to a new Harris survey 72% of patients with non-muscle invasive bladder cancer express a preference to keep chemotherapy as a later option in their treatment plan instead of a first-line approach. At ImmunityBio we're working to develop patient-focused approaches that help the immune system target cancer cells. Read more: https://immunitybio.com/new-survey-reveals-non-muscle-invasive-bladder-cancer-patients-seek-more-care-conversations/ https://immunitybio.com/new-survey-reveals-non-muscle-invasive-bladder-cancer-patients-seek-more-care-conversations/"
X Link 2025-12-09T15:08Z 16.4K followers, [----] engagements

"Non-muscle invasive bladder cancer is challenging due to its tendency to recur often bringing financial strain and reduced quality of life for patients. At ImmunityBio we're dedicated to bringing forward new therapies that offer meaningful hope to those navigating this condition. Learn more about our efforts in the bladder cancer space: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2025-12-11T18:04Z 16.4K followers, [----] engagements

"New data from our Phase 2/3 study shows that ANKTIVA (nogapendekin alfa inbakicept) plus BCG demonstrated a 96% overall survival rate at three years in patients with BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer (NMIBC). These findings add to the clinical significance of immunotherapy's role in bladder cancer a space where treatment options have historically been limited. Read more:"
X Link 2025-12-16T15:04Z 16.4K followers, 10.4K engagements

"As we reflect on the year behind us we're grateful for the progress made through science collaboration and shared purpose. Without the patients caregivers healthcare heroes researchers and our amazing team this year's progress would not have been possible. At ImmunityBio our work continues with a clear focus: advancing therapies that support better patient outcomes. We wish you health and peace this holiday season. https://twitter.com/i/web/status/2004218295092686957 https://twitter.com/i/web/status/2004218295092686957"
X Link 2025-12-25T15:50Z 16.4K followers, [----] engagements

"ImmunityBio's Founder Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong has been recognized by @oncodaily as one of The [---] Most Influential People in Oncology in [----]. Dr. Soon-Shiong has earned this honor in recognition of his lifelong commitment to science medicine and patient care a commitment that inspires our team and our partners every day said Richard Adcock President and CEO of ImmunityBio. His ideas and leadership are a driving force powering our mission to bring transformative therapies to people living with cancer and other serious"
X Link 2025-12-29T14:07Z 16.4K followers, [----] engagements

"As we reflect on [----] we recognize a year shaped by collaboration scientific progress and meaningful engagement across the healthcare community. From connecting with patients and their caregivers to working cross-functionally as a means of moving initiatives forward each effort contributed to strengthening our mission and vision. Looking ahead to [----] we remain focused on building on this momentum; continuing to advance our science and support important communities with purpose and intention. Learn more about our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2026-01-01T19:07Z 16.4K followers, [----] engagements

"ImmunityBio and @MSFTResearch donate a combined [--] petaflops of GPU computing power to create models for researchers working on #coronavirus vaccines & therapeutics. Models can be derived in days rather than the months it would normally require. https://immunitybio.com/immunitybio-combines-supercomputing-power-with-microsoft-azure-to-target-infection-doorway-of-the-coronavirus/ https://immunitybio.com/immunitybio-combines-supercomputing-power-with-microsoft-azure-to-target-infection-doorway-of-the-coronavirus/"
X Link 2020-04-01T12:35Z 16.5K followers, [---] engagements

"We're honored to be partnering with #IDRI & Texas Children's Hospital Center for Vaccine Development on 2nd gen COVID-19 vaccines #COVID19 $IBRX https://www.axios.com/the-new-covid-vaccine-rivals-f833eb14-855d-49c7-863e-000f7c45b21a.html https://www.axios.com/the-new-covid-vaccine-rivals-f833eb14-855d-49c7-863e-000f7c45b21a.html"
X Link 2021-11-05T16:59Z 16.5K followers, [--] engagements

"Until we have a second-generation vaccine that actually stops transmission the pandemic will not be over shared ImmunityBio Founder @drpatrick today on @QuestMeans. ImmunityBio is proud to begin phase [--] clinical trials for our COVID vaccine in Africa next week. $IBRX Botswana is getting big investment in a COVID vaccine center. ImmunityBio Founder and Executive Chairman Patrick Soon-Shiong talks about his investment in the center and what increased access to vaccines would mean globally. https://t.co/wujXdA3H0a Botswana is getting big investment in a COVID vaccine center. ImmunityBio Founder"
X Link 2021-12-16T22:50Z 16.5K followers, [---] engagements

"Thrilled about the news that our partners Drs. Hotez and Bottazzi have been nominated for the Nobel Prize for their work on low-cost #COVID-19 vaccine thats already in use in India. Congratulations on the well-deserved recognition @TexasChildrens @PeterHotez @mebottazzi"
X Link 2022-02-16T22:24Z 16.5K followers, [---] engagements

"Latest data from the QUILT [--] trial shows Nant Cancer Vaccine more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer. Principal Investigator Dr. Tara Seery presented the poster at #ASCO22 Abstract #4147 poster #132"
X Link 2022-06-05T15:42Z 16.5K followers, [--] engagements

"Tomorrow we are participating in the @WhiteHouse summit on next-generation #COVID vaccines. Our vaccine candidates are designed to thwart future coronavirus variants and provide longer duration protection. Tune in here: @WHCOVIDResponse https://bit.ly/3J2yYmT https://bit.ly/3J2yYmT"
X Link 2022-07-25T19:19Z 16.5K followers, [--] engagements

"We're pleased to share the FDA has accepted for review our BLA for N-803+BCG for BCG-unresponsive NMIBC. With this important step we're closer to being able to offer a promising combo therapeutic to people living w/ #NMIBC and ultimately reducing the incidence of cystectomies"
X Link 2022-07-28T20:19Z 16.5K followers, [--] engagements

"Were thrilled to announce today @US_FDA approved a first-in-class treatment for BCG-unresponsive non-muscle invasive bladder cancer #NMIBC. Learn more: $IBRX https://immunitybio.com/immunitybio-announces-fda-approval-of-anktiva-first-in-class-il-15-receptor-agonist-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer/ https://immunitybio.com/immunitybio-announces-fda-approval-of-anktiva-first-in-class-il-15-receptor-agonist-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer/"
X Link 2024-04-23T02:12Z 16.5K followers, [----] engagements

"In an interview today with @YahooFinance ImmunityBio Chairman @drpatrick spoke with @AnjKhem about what the approval of #Anktiva means for ImmunityBio as well as investors. Check out their conversation here $IBRX Anktiva is the next-generation immunotherapy drug according to ImmunityBio executive chairman Dr. Patrick Soon-Shiong: "This drug is the first drug as far as I know that activates the natural killer cell that talks to the T-cell and generates complete remission." https://t.co/DIVc3A8luy Anktiva is the next-generation immunotherapy drug according to ImmunityBio executive chairman Dr."
X Link 2024-04-23T21:56Z 16.5K followers, 10.8K engagements

"ICYMI: ImmunityBio management recently provided an update on registration plans for #NSCLC status of #ANKTIVA launch readiness for #NMIBC and ANKTIVA as the backbone of companys clinical trial pipeline for multiple tumor types. Learn more: https://immunitybio.com/investor-live-audio-webcast-anktiva-post-approval/ https://immunitybio.com/investor-live-audio-webcast-anktiva-post-approval/"
X Link 2024-04-27T19:59Z 16.5K followers, [----] engagements

"In an interview with @TeamCavuto on @FoxBusiness ImmunityBio founder @drpatrick highlighted the unique mechanism of action for Anktiva and reiterated our belief in Anktiva and its potential efficacy as a next-generation immunotherapy across multiple tumor types. $IBRX"
X Link 2024-05-02T17:29Z 16.5K followers, [----] engagements

"ICYMI: @drpatrick participated in a fireside chat with Dr. Sam Chang at #AUA24: https://www.auadailynews.org/meeting-coverage/article/22908979/a-new-frontier-of-immunotherapy-for-bladder-cancer https://www.auadailynews.org/meeting-coverage/article/22908979/a-new-frontier-of-immunotherapy-for-bladder-cancer"
X Link 2024-05-04T14:51Z 16.5K followers, [----] engagements

"The FDA's green light for our first-in-class IL-15 receptor marks a new era in treating #NMIBC. In this interview with @UrologyTimes @drpatrick sheds light on the pivotal approval. #IBRX #BladderCancer https://bit.ly/4b9qg3c https://bit.ly/4b9qg3c"
X Link 2024-05-09T00:34Z 16.5K followers, [----] engagements

"Thank you Howard Fine at @LABJnews for covering the many exciting happenings at ImmunityBio - including the progress and future of our newly FDA-approved #immunotherapy.🧪🔬 https://labusinessjournal.com/healthcare/immunitybio-advances-on-the-anktiva-front/ https://labusinessjournal.com/healthcare/immunitybio-advances-on-the-anktiva-front/"
X Link 2024-05-15T22:10Z 16.5K followers, [----] engagements

"Interested in hearing more about our newly approved bladder cancer immunotherapy Check out new interviews with @drpatrick and Dr. Bobby Reddy on the @urotoday podcast series with @UroDocAsh here: https://immunitybio.com/connecting-the-dots-of-anktivas-triangle-offense-a-deep-dive-with-dr-patrick-soon-shiong-and-dr-ashish-kamat-in-a-three-part-urotoday-podcast/ https://immunitybio.com/connecting-the-dots-of-anktivas-triangle-offense-a-deep-dive-with-dr-patrick-soon-shiong-and-dr-ashish-kamat-in-a-three-part-urotoday-podcast/"
X Link 2024-05-17T13:41Z 16.5K followers, [----] engagements

"Were looking forward to meeting with healthcare providers at the Large Urology Group Practice Association (LUGPA) regional meeting this week in Las Vegas and sharing ideas and advancing our understanding of treating bladder cancer. https://www.lugpa.org/vegas-regional-2024 https://www.lugpa.org/vegas-regional-2024"
X Link 2024-06-06T17:39Z 16.5K followers, [----] engagements

"Lung cancer is the leading cause of cancer death in the US killing [------] annually. Over [------] are diagnosed each year most with non-small cell lung cancer. A form where more advances are needed and we're working on better treatments. Learn more at http://ImmunityBio.com http://ImmunityBio.com"
X Link 2024-06-14T18:10Z 16.5K followers, [----] engagements

"ImmunityBio is pleased to announce positive results from our QUILT [-----] trial showing extended survival of [--] months to [--] years for lung cancer patients treated with checkpoint inhibitors. Read more: https://immunitybio.com/immunitybio-presents-positive-long-term-overall-survival-data-in-non-small-cell-lung-cancer-patients-and-announces-registrational-intent-phase-3-trials-with-anktiva-and-checkpoint-immunotherapy/"
X Link 2024-09-09T13:03Z 16.5K followers, 29.4K engagements

"Yesterdays investor meeting was an important moment to align with key opinion leaders and shareholders on our continued progress toward delivering better treatment options for patients"
X Link 2025-04-16T14:33Z 16.5K followers, [----] engagements

"ImmunityBio is excited to showcase our latest advancements in bladder and prostate cancer at the American Urological Association Annual Meeting. Learn more about our keynote presentations: https://immunitybio.com/immunitybio-to-showcase-advances-for-bladder-and-prostate-cancer-at-american-urological-association-aua-annual-meeting/ https://immunitybio.com/immunitybio-to-showcase-advances-for-bladder-and-prostate-cancer-at-american-urological-association-aua-annual-meeting/"
X Link 2025-04-21T20:49Z 16.5K followers, [----] engagements

"Did you know that certain occupations carry a higher risk of bladder cancer due to exposure to harmful chemicals An estimated 10% of all bladder cancer cases are considered occupational meaning they can be attributed to exposure to cancer-causing agents at work. Learn more about how we're advancing bladder cancer treatment and support for those affected: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2025-05-19T14:52Z 16.5K followers, [----] engagements

"Our dedication fuels breakthrough innovations aiming to improve outcomes for all patients. Learn more about our founder's vision: https://immunitybio.com/founders-vision/ https://immunitybio.com/founders-vision/"
X Link 2025-05-28T13:52Z 16.5K followers, [----] engagements

"As Bladder Cancer Awareness Month concludes our hearts remain with those affected. ImmunityBio is committed to advancing care and supporting patients every step of the way"
X Link 2025-05-29T14:16Z 16.5K followers, [----] engagements

"We've announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access authorization for the use of our Cancer BioShield platform anchored by ANKTIVA to treat lymphopenia in adult patients with refractory or relapsed solid tumors who have progressed after first-line standard-of-care treatment chemotherapy radiation or immunotherapy. Learn more: https://immunitybio.com/immunitybio-receives-fda-expanded-access-authorization-for-landmark-treatment-of-lymphopenia-with-anktiva-the-cancer-bioshield-platform-in-patients-with-solid-tumors/"
X Link 2025-06-02T14:10Z 16.5K followers, 10.2K engagements

"At ImmunityBio we're redefining cancer care. Our mission focuses on developing treatments that are not only effective but also aim to enhance patient comfort. Our team works to improve the experiences of those undergoing cancer treatment offering hope through innovative therapies. Learn more about our vision: https://immunitybio.com/founders-vision/ https://immunitybio.com/founders-vision/"
X Link 2025-06-03T14:02Z 16.5K followers, [----] engagements

"Lynch syndrome affects an estimated [--] in [---] in the U.S. emphasizing the importance of awareness and early detection in order to prevent cancers like colon cancer. ImmunityBios investigational study aims to improve outcomes for those affected. Learn more: https://immunitybio.com/lynch-syndrome/ https://immunitybio.com/lynch-syndrome/"
X Link 2025-06-09T14:32Z 16.5K followers, [----] engagements

"We are happy to share that as a proud sponsor of the SITC event at Buddy Guys Legends we helped raise over $60000 through the Forward Fund. These funds will directly support the programs awards and grants that advance the professional development of investigators ensuring a bright future for innovation in immunotherapy"
X Link 2025-06-23T15:23Z 16.5K followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing